Envista Holdings Q2 sales beat estimates, 2025 guidance raised
Overview
Envista Q2 sales beat analyst expectations, reaching $682 mln, per LSEG data
Adjusted EPS for Q2 rises 136% yr/yr, reflecting strong profitability
Co raises full-year 2025 guidance, indicating confidence in continued growth
Outlook
Envista raises 2025 core sales growth guidance to 3%-4%
Company increases 2025 adjusted EPS guidance to $1.05-$1.15
Envista maintains 2025 adjusted EBITDA margin guidance at ~14%
Result Drivers
GEOGRAPHIC GROWTH - Positive growth across all major businesses and geographies, including Nobel Biocare in North America
OPERATIONAL IMPROVEMENTS - Envista Business System (EBS) contributed to continued improvement in Spark margins
EMPLOYEE ENGAGEMENT - Sustained improvement in employee engagement and development, as noted by the company
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | $682.10 mln | $640.20 mln (12 Analysts) |
Q2 Adjusted Net Income |
| $44 mln |
|
Q2 Net Income |
| $26 mln |
|
Q2 Adjusted EBITDA |
| $84 mln |
|
Q2 Gross Profit |
| $369.90 mln |
|
Q2 Operating Profit |
| $46.30 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Envista Holdings Corp is $20.00, about 0.2% above its July 30 closing price of $19.96
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 17 three months ago
Press Release: ID:nPn6LJQHZa
